NEW YORK – BillionToOne said on Tuesday that it has raised $15 million in a Series A follow-on financing round, bringing the Menlo Park, California-based firm's total funding to date to more than $32.5 million.
Previous investors Hummingbird Ventures and NeoTribe Ventures led the round, with participation from Y Combinator, Libertus Capital, Pacific 8 Ventures, Civilization Ventures, 500 Startups Istanbul, and HOF Capital.
The new funding follows a $15 million Series A round the company closed a year ago.
BillionToOne plans to use the new cash to support the commercial expansion of its noninvasive prenatal Unity test to all US states and to fund R&D for future diagnostic tests, including liquid biopsy assays.
The Unity test, launched last year, assays a pregnant woman's blood to screen for common and severe inherited disorders, such as cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies. It is a carrier screening test with a reflex NIPT if the mother tests positive. Unity is currently available for order in all US states except New York, as well as in select international countries.
The company plans to expand the capacity of its CLIA laboratory more than twentyfold and to increase its commercial team to up to 50 account executives.
"We are delighted with the surging demand in the market for Unity," said Firat Ileri of Hummingbird Ventures in a statement. "With additional novel clinical products in the pipeline, we are more confident than ever for the future growth of BillionToOne."